Nicotinamide riboside chloride
(Synonyms: 烟酰胺核糖氯酸盐) 目录号 : GC36738
Nicotinamide riboside chloride是一种新型的维生素B₃补充剂，也被证明是一种可口服的NAD⁺（烟酰胺腺嘌呤二核苷酸）前体，能够使哺乳动物细胞中的NAD⁺水平大致增加一倍。
Cas No.:23111-00-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Nicotinamide riboside chloride, a new form of vitamin B3 supplement, has also been shown to be an NAD+ precursor that is orally available and can roughly double the level of NAD+ in mammalian cells[1].
In vitro, Nicotinamide riboside chloride (800μM) can inhibit ferroptosis by suppressing excessive mitophagy and reducing iron accumulation, while restoring mitochondrial function and osteogenic capacity in MC3T3-E1 pre-osteoblasts[2]. In H9c2 cells, Nicotinamide riboside chloride (0, 0.01, 0.1, 1, 5 and 10mM; 24h) pretreatment reduced the levels of lactate dehydrogenase, CK-MB, malondialdehyde, superoxide dismutase and ROS, and reduced cell mortality after the induction of hypoxia/reoxygenation (H/R) injury[3].
In vivo, Acute treatment with Nicotinamide riboside chloride (300mg/kg; 20min after reperfusion; i.p.) reduces hippocampal damage and preserves the cognitive function of mice with ischemic injury[4]. Nicotinamide riboside chloride (500mg/kg; daily; i.p.) treatment improved cardiac dysfunction and blocked progression of heart failure in both WT and Sirt3 KO mice[5].
References:
[1] Zarei A, Khazdooz L, Madarshahian S, et al. Synthesis, Stability, and Bioavailability of Nicotinamide Riboside Trioleate Chloride. Nutrients. 2021 Dec 27;14(1):113.
[2] Hu Y, Lu H, Fang H, et al. Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis. Int J Surg. 2025 Jul 2.
[3] Yuan C, Yang H, Lan W, et al. Nicotinamide ribose ameliorates myocardial ischemia/reperfusion injury by regulating autophagy and regulating oxidative stress. Exp Ther Med. 2024 Mar 7;27(5):187.
[4] Cheng YH, Zhao JH, Zong WF, et al. Acute Treatment with Nicotinamide Riboside Chloride Reduces Hippocampal Damage and Preserves the Cognitive Function of Mice with Ischemic Injury. Neurochem Res. 2022 Aug;47(8):2244-2253.
[5] Walker MA, Chen H, Yadav A, et al. Raising NAD+ Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation. Circulation. 2023 Dec 19;148(25):2038-2057.
Nicotinamide riboside chloride是一种新型的维生素B₃补充剂，也被证明是一种可口服的NAD⁺（烟酰胺腺嘌呤二核苷酸）前体，能够使哺乳动物细胞中的NAD⁺水平大致增加一倍[1]。
在体外实验中，Nicotinamide riboside chloride（800μM）可以通过抑制过度的线粒体自噬和减少铁积累来抑制铁死亡（ferroptosis），同时恢复MC3T3-E1前成骨细胞的线粒体功能和成骨能力[2]。在H9c2细胞中，Nicotinamide riboside chloride（0, 0.01, 0.1, 1, 5和10mM; 24小时）预处理降低了乳酸脱氢酶、肌酸激酶同工酶（CK-MB）、丙二醛、超氧化物歧化酶和活性氧（ROS）的水平，并减少了缺氧/复氧（H/R）损伤诱导后的细胞死亡率[3]。
在体内实验中，Nicotinamide riboside chloride急性处理（300mg/kg; 复灌后20分钟; 腹腔注射）可减少缺血损伤小鼠海马区的损伤并保护其认知功能[4]。Nicotinamide riboside chloride（500mg/kg; 每日; 腹腔注射）治疗改善了野生型（WT）和Sirt3基因敲除（KO）小鼠的心脏功能障碍，并阻止了心力衰竭的进展[5]。
| Cell experiment [1]: | |
Cell lines | H9c2 cells |
Preparation Method | Prior to simulating ischemia-reperfusion (I/R) injury, the cell culture medium was discarded, the cells were rinsed with PBS, and DMEM without fetal bovine serum (FBS) was added. The cells were then cultured for 24h. First, the effect of treatment with different concentrations of Nicotinamide riboside chloride alone on the survival of H9c2 cells was investigated. The cells were pre-treated with different concentrations of Nicotinamide riboside chloride, and their survival status was determined using a Cell Counting Kit-8 (CCK-8) assay. Second, the minimum effective concentration of Nicotinamide riboside chloride for protecting against H/R injury was determined. The cells were pre-treated with different concentrations of Nicotinamide riboside chloride followed by H/R treatment, and cell survival status was detected using the CCK-8 assay. In these experiments, various dilutions of Nicotinamide riboside chloride (0, 0.01, 0.1, 1, 5 and 10mM) were prepared using DMEM. The cells were seeded in six-well plates and treated with the different dilutions of Nicotinamide riboside chloride. The cells were pre-treated with Nicotinamide riboside chloride at 37°C for 24h. Subsequently, the cells were placed in a three-gas anoxic incubator (1% O₂ + 94% N₂ + 5% CO₂) for 3h. After this hypoxic treatment, the cell culture medium was replaced with DMEM containing 10% FBS, and the plate was placed in a normal 37°C incubator with 95% air and 5% CO₂ for another 3h. The cell culture supernatant was then collected and transferred to an Eppendorf tube, which was stored in a -80°C freezer for later use. The control group consisted of normally cultured cells without any treatment; the H/R group was cultured at 37°C for 3h in an anoxic incubator; the H/R + Nicotinamide riboside chloride group was pre-treated with Nicotinamide riboside chloride for 24h before undergoing hypoxia-reoxygenation; the H/R + Nicotinamide riboside chloride + EX527 and Nicotinamide riboside chloride + EX527 groups were pre-treated with Nicotinamide riboside chloride and EX527 for 24h before undergoing hypoxia-reoxygenation. |
Reaction Conditions | 0, 0.01, 0.1, 1, 5 and 10mM; 24h |
Applications | In H9c2 cells, Nicotinamide riboside chloride pretreatment reduced the levels of lactate dehydrogenase, CK-MB, malondialdehyde, superoxide dismutase and ROS, and reduced cell mortality after the induction of hypoxia/reoxygenation (H/R) injury. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6 mice |
Preparation Method | Pathologic hypertrophy was induced by treating male (3-4 months old) Sirt3 KO and WT mice with isoproterenol (ISO) or vehicle for 14 days. Mice with and without GW6471(4.5mg/kg/day) were treated with Nicotinamide riboside chloride (500mg/kg; daily; i.p.) or vehicle starting at day one after mini-pump insertion. Briefly, an incision was made in the skin between the shoulder blades. A deep subcutaneous pocket was made caudal to the incision using blunt dissection. The sterile minipump was inserted into the pocket, and the incision was closed with wound clips. Isoproterenol (30mg/kg/day) was delivered by osmotic minipump for 14 days. Minipumps carrying saline were used as a control. |
Dosage form | 500mg/kg; daily; i.p. |
Applications | Nicotinamide riboside chloride treatment improved cardiac dysfunction and blocked progression of heart failure in both WT and Sirt3 KO mice. |
References: | |
| Cas No. | 23111-00-4 | SDF | |
| 别名 | 烟酰胺核糖氯酸盐 | ||
| Canonical SMILES | NC(C1=C[N+]([C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)=CC=C1)=O.[Cl-] | ||
| 分子式 | C11H15ClN2O5 | 分子量 | 290.7 |
| 溶解度 | Water : 250 mg/mL (859.99 mM) | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.44 mL | 17.1999 mL | 34.3997 mL |
| 5 mM | 0.688 mL | 3.44 mL | 6.8799 mL |
| 10 mM | 0.344 mL | 1.72 mL | 3.44 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet